04:14 AM EDT, 06/17/2024 (MT Newswires) -- Innate Pharma ( IPHA ) said Monday that updated results from the dose-escalation part of a phase 1/2 study of CD123 targeting the so-called Natural Killer Cell Engager "continues to show promising and durable clinical efficacy along with a favorable safety profile."

The results for SAR443579/IPH6101, targeting NKp46/CD16-based Natural Killer Cell Engager, come from a research collaboration between Innate Pharma ( IPHA ) and Sanofi (SNY).

The study, led by Sanofi, tests SAR'579 as a monotherapy for blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplasia.

The company said the monotherapy has the Food and Drug Administration's fast-track designation to treat acute myeloid leukemia.